Serial detection of Epstein–Barr virus DNA in sera and peripheral blood leukocyte samples of pediatric renal allograft recipients with persistent mononucleosis‐like symptoms defines patients at risk to develop post‐transplant lymphoproliferative disease
- 12 February 2003
- journal article
- case report
- Published by Wiley in Pediatric Transplantation
- Vol. 7 (1) , 46-52
- https://doi.org/10.1034/j.1399-3046.2003.02051.x
Abstract
We tested blood samples of 25 pediatric renal transplant recipients for Epstein-Barr virus (EBV) DNA load by quantitative polymerase chain reaction (PCR). Eleven of these transplant recipients showed clinical persistent mononucleosis-like symptoms years after transplantation (Tx). A quantitation of EBV DNA by PCR in peripheral blood lymphocyte (PBL) and serum samples revealed variable EBV DNA titers. The majority of EBV PCR results in samples of the 14 asymptomatic transplant recipients was repeatedly below detection limit. In contrast, patients with mononucleosis-like symptoms showed persistent EBV genome titers over a period of 6 months, ranging from 75 to 18 750 copies/10 000 PBL and from 680 to 335 000 copies/mL serum, respectively. One child suffering from this mononucleosis-like condition developed an EBV-associated Burkitt-like lymphoma 29 months after Tx. Whereas clinical and histological investigations did not indicate a post-transplant lymphoproliferative disorder (PTLD) until tumor detection, EBV titers in PBL and serum had been high for at least 8 months. We propose that pediatric transplant recipients who show both, recurrent mononucleosis-like symptoms and a sustained high EBV genome load, are at increased risk for severe EBV-related post-transplant complications.Keywords
This publication has 14 references indexed in Scilit:
- Primary tacrolimus (FK506) therapy and the long‐term risk of post‐transplant lymphoproliferative disease in pediatric liver transplant recipientsPediatric Transplantation, 2001
- The Epstein–Barr virus and post‐transplant lymphoproliferative disease: interplay of immunosuppression, EBV, and the immune system in disease pathogenesisTransplant Infectious Disease, 2001
- POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERS IN ADULT AND PEDIATRIC RENAL TRANSPLANT PATIENTS RECEIVING TACROLIMUS-BASED IMMUNOSUPPRESSION1Transplantation, 1999
- EPSTEIN-BARR VIRUS-RELATED DISORDERS IN CHILDREN UNDERGOING RENAL TRANSPLANTATION WITH TACROLIMUS-BASED IMMUNOSUPPRESSIONTransplantation, 1999
- PROSPECTIVE LONGITUDINAL ANALYSIS OF QUANTITATIVE EPSTEIN-BARR VIRUS POLYMERASE CHAIN REACTION IN PEDIATRIC LIVER TRANSPLANT RECIPIENTSTransplantation, 1999
- POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE IN PEDIATRIC LIVER TRANSPLANTATIONTransplantation, 1996
- THE FREQUENCY OF EPSTEIN-BARR VIRUS INFECTION AND ASSOCIATED LYMPHOPROLIFERATIVE SYNDROME AFTER TRANSPLANTATION AND ITS MANIFESTATIONS IN CHILDRENTransplantation, 1988
- Epstein-Barr Virus Infections and DNA Hybridization Studies in Posttransplantation Lymphoma and Lymphoproliferative Lesions: The Role of Primary InfectionThe Journal of Infectious Diseases, 1985
- REVERSIBILITY OF LYMPHOMAS AND LYMPHOPROLIFERATIVE LESIONS DEVELOPING UNDER CYCLOSPORIN-STEROID THERAPYThe Lancet, 1984
- Epstein–Barr Virus-Induced B-Cell Lymphoma after Renal TransplantationNew England Journal of Medicine, 1982